Verastem, Inc.
VSTM Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$10.10
KIRA · Stoqly’s AI analyst, in plain words
- Verastem, Inc. had $30.9M of revenue in fiscal 2025, up 209.1% on the year before. Over five years, revenue changed −19.0% a year on average.
- Its operating margin was −550.3%, up 599.2 pts: of every 100 in sales, about −550 is left after running the business.
- Verastem, Inc. lost $209M in fiscal 2025.
Market cap
$1.0B
P/E
—
Revenue
$30.9M
Net income
−$209M
Free cash flow
—
Operating margin
−550.3%
Verastem, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+209.1%
Yes. Sales grew 209.1% last year.
Does it make a profit?
−677.6%
No. It lost money last year.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Verastem, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 4, 2026
- Legal name
- Verastem, Inc.
- CIK
- 0001526119
Verastem, Inc. · VSTM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.1M | $2.6M | — | $10.0M | $30.9M |
| Revenue growth | −97.7% | 26.4% | — | — | 209.1% |
| Operating margin | −2,991.2% | −2,809.6% | — | −1,149.6% | −550.3% |
| Net income | −$71.2M | −$73.8M | −$87.4M | −$131M | −$209M |
| Net margin | −3,468.1% | −2,843.3% | — | −1,306.4% | −677.6% |
| Diluted EPS | −$4.90 | −$4.57 | −$3.96 | −$3.66 | −$3.02 |
| Cash | |||||
| Cash from operations | −$53.5M | −$63.7M | −$86.5M | −$105M | −$138M |
| Capital expenditure | $0.2M | — | — | $0.0M | — |
| Free cash flow | −$53.7M | — | — | −$105M | — |
| FCF margin | −2,615.6% | — | — | −1,048.0% | — |
| Share count change | 9,381.4% | 11.0% | 36.7% | 61.9% | 94.1% |
| Debt and strength | |||||
| Cash and short-term investments | $100M | $87.9M | $137M | $88.8M | $205M |
| Debt incl. finance leases | — | $24.5M | $40.1M | $40.7M | — |
| Shareholders' equity | $87.6M | $47.4M | $57.4M | −$28.9M | $57.2M |
| Current ratio | 5.7x | 4.3x | 5.4x | 3.1x | 3.1x |
| Interest coverage | −6.2x | −34.1x | −22.2x | −25.2x | −149.5x |
| Returns and quality | |||||
| Return on equity | −70.2% | −109.4% | −166.8% | −917.4% | −1,480.2% |
| Return on tangible equity | −81.3% | −155.8% | −152.3% | — | −513.8% |
| Piotroski F-score | 1 | 2 | 3 | 1 | 4 |
| Altman Z'' | −14.1 | −24.5 | −16.1 | −34.4 | −15.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.1M
6 insiders
Of sales under plans
100%
$1.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Verastem, Inc. · VSTM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.10 a share, the company is worth $1.0B.
Source: SEC EDGAR XBRL filings (CIK 0001526119). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.